Tempest Therapeutics(TPST.US) Officer Buys US$73,850 in Common Stock
$Tempest Therapeutics(TPST.US)$ Officer Brady Stephen R purchased 35,000 shares of common stock on Jul 3, 2024 at an average price of $2.11 for a total value of $73,850. Source: Announcemen
Tempest Therapeutics(TPST.US) Officer Buys US$9,951.36 in Common Stock
$Tempest Therapeutics(TPST.US)$ Officer Whiting Samuel purchased 4,672 shares of common stock on Jul 2, 2024 at an average price of $2.13 for a total value of $9,951.36.Source: Announcement What is st
Tempest Therapeutics(TPST.US) Officer Buys US$16,200 in Common Stock
$Tempest Therapeutics(TPST.US)$ Officer Trojanowski Justin purchased 7,500 shares of common stock on Jun 28, 2024 at an average price of $2.16 for a total value of $16,200.Source: Announcement What is
Tempest and SnapSea Announce Strategic Partnership
Collaboration to enhance destination marketing, boost engagement and drive visitation with advanced user-generated content solutions PHILADELPHIA,, July 1, 2024 /PRNewswire/ -- Tempest, a leader in w
Tempest Launches Sports Tourism Index 2.0
Brand new platform introduces exciting new benefits and capabilities for destination organizations and sports events rights holders, alongside sweeping enhancements to existing features PHILADELPHIA,
Tempest Therapeutics Price Target Maintained With a $8.00/Share by Piper Sandler
Tempest Therapeutics Price Target Maintained With a $8.00/Share by Piper Sandler
Express News | Piper Sandler Reiterates Overweight on Tempest Therapeutics, Maintains $8 Price Target
Scotiabank Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Maintains Target Price $13
Scotiabank analyst George Farmer maintains $Tempest Therapeutics(TPST.US)$ with a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 46.6%
Tempest Therapeutics Shares Are Trading Lower. The Company Announced Data From the Ongoing Global Randomized Phase 1b/2 Clinical Study for Amezalpat2.
Tempest Therapeutics Shares Are Trading Lower. The Company Announced Data From the Ongoing Global Randomized Phase 1b/2 Clinical Study for Amezalpat2.
Express News | HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Tempest Falls After New Trial Data for Liver Cancer Therapy
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
Shares of Tempest Therapeutics Inc (NASDAQ:TPST) are trading lower on Thursday, with a session volume of 21 million as per data from Benzinga Pro.The company announced new data from the ongoing Phase
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market trading after the company disclosed a strategic partnership with Avegant to develop optimized waveguide optical modules for
Express News | Tempest Therapeutics Inc: Post Sales Agreement, Will Be Able to Offer and Sell up to $205 Mln of Shares of Common Stock
Express News | Tempest Therapeutics: Co & Agent Terminated Prior Sales Agreement, Entered New Open Market Sale Agreement
Market-Moving News for June 20th
HROW: 20% | Harrow shares are trading higher after the company announced the manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL. Also th
NVIDIA Stock Gains Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively traded Invesco QQQ Trust (QQQ) was 0.6% higher in Thursday's premarket activity pushed by the continued
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersTempest Therapeutics (NASDAQ:TPST) shares rose 32.8% to $3.79 during Thursday's pre-market session. The company's market cap stands at $84.0 million. Neurogene (NASDAQ:NGNE) shares rose 31.92%
Express News | Tempest Therapeutics Inc: Randomized Arms Were Generally Well Balanced at Baseline
Express News | Tempest Therapeutics Inc: Amezalpat Remains Well Tolerated